New hope for tough breast cancer: experimental drug enters final testing phase

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. About 418 adults who have had 1-2 prior chemotherapy treatments will be randomly assigned to receive either the new drug or a standard chemotherapy chosen by their doctor. The main goals are to see if the new drug helps patients live longer without their cancer getting worse and if it improves overall survival compared to standard options.